Note: This stock was recommended for a 'watch item' position exclusively to Biotech Forum members one month ago when the stock traded at approximately $5.50 a share.
We often miss opportunity because it's dressed in overalls and looks like work”? Thomas A. Edison
Today, we revisit an interesting 'Tier 4' biotech concern headquartered 'across the pond'.
NuCana (NCNA) is a United Kingdom-based clinical-stage biopharmaceutical company that IPO’d in 2017. The firm is developing novel cancer therapeutics called ProTides. The company’s pipeline consists of three drugs: Acelarin, NUC-3373 and NUC-7738. Acelarin